Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways

摘要

a Bioinformatics analysis of the expression of the ANT1 gene (SLC25A4) and of some of its partners in a cohort of non-tumoral muscle (n = 6), ERMS (n = 8), and ARMS (n = 10) from the {"type":"entrez-geo","attrs":{"text":"GSE28511","term_id":"28511"}}GSE28511 transcriptomic dataset. ***p < 0.001; two-sided independent samples T-test. b Quantification of ANT1 gene (SLC25A4) expression by RT-qPCR, relative to the housekeeping gene HPRT in RMS biopsies (n = 67), normal adult muscle (n = 5), fetal muscle (n = 9), and in biopsies from patients with muscle weakness (BD Becker dystrophy, DMD Duchenne muscular dystrophy, n = 5 each). *p < 0.05, **p < 0.01, ns not significant; two-sided independent samples T-test. c Quantification of ANT1 expression by RT-qPCR, relative to the housekeeping gene HPRT in ERMS cell lines (RD and A-204), and ARMS cell lines (RH30 and RH41). Results are presented as means ± s.d.; n = 3. d Efficiency of ANT1 silencing by CRISPR-Cas9 in RD cells, 48 h after doxycycline treatment. Quantification of ANT1 expression by RT-qPCR, relative to the housekeeping gene HPRT. Results are presented as means ± s.d.; n = 3. *p < 0.05; two-sided independent samples T-test. e Increase in number of metabolically active cells as measured by WST-1 assay in RDLow cells, at different time points after silencing of ANT1 expression by doxycycline treatment. Results are presented as means ± s.d.; n = 3. **p < 0.01, ****p < 0.0001; two-sided independent samples T-test.